Journal of cancer research and therapeutics最新文献

筛选
英文 中文
Surgery or radiotherapy improves survival in elderly patients with early non-small cell lung cancer: A population-based analysis. 手术或放疗可提高早期非小细胞肺癌老年患者的生存率:基于人群的分析
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_973_23
Pingfan Shi, Ziye Li, Yanfei Zhang, Changxing Shen, Qing Xia, Chuanwu Cao, Ming Li, Lihong Fan
{"title":"Surgery or radiotherapy improves survival in elderly patients with early non-small cell lung cancer: A population-based analysis.","authors":"Pingfan Shi, Ziye Li, Yanfei Zhang, Changxing Shen, Qing Xia, Chuanwu Cao, Ming Li, Lihong Fan","doi":"10.4103/jcrt.jcrt_973_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_973_23","url":null,"abstract":"<p><strong>Objective: </strong>There is a lack of evidence to support a consensus on whether surgery or radiotherapy is optimal for elderly or very elderly patients with early-stage non-small cell lung cancer (NSCLC). We aimed to assess the impact of surgery or radiotherapy on survival in elderly (≥70 years) and very elderly (≥80 years) patients with early-stage NSCLC.</p><p><strong>Methods: </strong>Patients aged ≥70 years diagnosed with early-stage NSCLC between January 1, 1975, and December 31, 2018, were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and cancer-specific survival (CSS) were assessed based on surgery, radiotherapy, and no-treatment groups.</p><p><strong>Results: </strong>Data for 15,224 NSCLC patients aged ≥70 years were collected, which consisted of 6949 (45.6%) patients who underwent surgery alone, 5014 (32.9%) who underwent radiotherapy alone, and 3261 (21.5%) who received no treatment. Surgery significantly improved patient survival compared with no treatment (MST: 74 months vs. 7 months, HR: 0.201, 95% CI: 0.186-0.217, P < 0.001), as did radiotherapy (MST: 28 months vs. 7 months, HR: 0.440; 95% CI: 0.413-0.469, P < 0.001). Surgery also resulted in improved survival compared with radiotherapy (74 months vs. 28 months, HR: 0.455; 95% CI: 0.430-0.482, P < 0.001). A similar conclusion was made from the analysis of CSS. A subgroup analysis further confirmed the survival benefits.</p><p><strong>Conclusions: </strong>The results of this large-scale retrospective study indicate that both surgery and radiotherapy significantly enhance survival outcomes in patients aged ≥70 or ≥80 years with early-stage NSCLC. The survival benefits of surgery were particularly notable.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1251-1257"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of GADD45G methylation in endometrial cancer: Insights into CDK1/CCNB1 activation and therapeutic opportunities. GADD45G 甲基化在子宫内膜癌中的作用:对 CDK1/CCNB1 激活和治疗机会的见解。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2103_23
Chunxiao Wang, Shuzhi Shan, Xinjun Li, Huifang Wang, Jie Qi, Sufen Zhao
{"title":"The role of GADD45G methylation in endometrial cancer: Insights into CDK1/CCNB1 activation and therapeutic opportunities.","authors":"Chunxiao Wang, Shuzhi Shan, Xinjun Li, Huifang Wang, Jie Qi, Sufen Zhao","doi":"10.4103/jcrt.jcrt_2103_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2103_23","url":null,"abstract":"<p><strong>Introduction: </strong>Accumulating evidence suggests the significant involvement of GADD45G in the development of various cancers. This study investigates GADD45G's involvement and methylation status in endometrial cancer (EC), along with molecular mechanisms and potential therapies.</p><p><strong>Methods: </strong>The expression of GADD45G in EC tissues and controls was evaluated using RNA-seq, quantitative real-time polymerase chain reaction (qRT-PCR), and western blotting (WB). Methylation-specific PCR (MSP) evaluated GADD45G's methylation status. Protein-protein interaction (PPI) prediction identified potential interactors of GADD45G, and co-immunoprecipitation (co-IP) confirmed GADD45G interact with Cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1). Several cell behavior assays were conducted in both in vitro and in vivo settings to comprehensively understand the impact of GADD45G dysregulation in EC.</p><p><strong>Results: </strong>Our findings revealed a significant decrease in the expression of GADD45G in endometrial cancer tissues and cells, which was attributed to its methylation status. Reduced GADD45G expression correlated with increased invasive behaviors in EC cells. Furthermore, GADD45G negatively regulated CDK1 and CCNB1, promoting invasive behaviors at transcript and protein levels.</p><p><strong>Conclusion: </strong>This study demonstrated that the downregulation of GADD45G, mediated by methylation, facilitates the invasive behaviors of EC cells through interaction with the CDK1/CCNB1. These findings enhance understanding of the molecular mechanisms underlying endometrial cancer and suggest potential therapeutic strategies targeting GADD45G for treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1214-1223"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral microbiome and its relationship with oral cancer. 口腔微生物群及其与口腔癌的关系。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_44_24
Shengran Wang, Xiao Tan, Juan Cheng, Zeyang Liu, Huiping Zhou, Jiyuan Liao, Xijun Wang, Hongyun Liu
{"title":"Oral microbiome and its relationship with oral cancer.","authors":"Shengran Wang, Xiao Tan, Juan Cheng, Zeyang Liu, Huiping Zhou, Jiyuan Liao, Xijun Wang, Hongyun Liu","doi":"10.4103/jcrt.jcrt_44_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_44_24","url":null,"abstract":"<p><strong>Abstract: </strong>As the initial point for digestion, the balance of oral microorganisms plays an important role in maintaining local and systemic health. Oral dysbiosis, or an imbalance in the oral microbial community, may lead to the onset of various diseases. The presence or abnormal increase of microbes in the oral cavity has attracted significant attention due to its complicated relationship with oral cancer. Oral cancer can remodel microbial profiles by creating a more beneficial microenvironment for its progression. On the other hand, altered microbial profiles can promote tumorigenesis by evoking a complex inflammatory response and affecting host immunity. This review analyzes the oncogenic potential of oral microbiome alterations as a driver and biomarker. Additionally, a potentially therapeutic strategy via the reversal of the oral microbiome dysbiosis in oral cancers has been discussed.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1141-1149"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of the three-dimensional visualization ablation planning system in ultrasound-guided percutaneous microwave ablation for malignant adrenal tumors: A clinical comparative study. 三维可视化消融计划系统在超声引导下经皮微波消融治疗恶性肾上腺肿瘤中的价值:临床比较研究。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2315_23
Qiaowei Du, Xin Li, Zheng Lin, Linan Dong, Fangyi Liu, Ping Liang
{"title":"Value of the three-dimensional visualization ablation planning system in ultrasound-guided percutaneous microwave ablation for malignant adrenal tumors: A clinical comparative study.","authors":"Qiaowei Du, Xin Li, Zheng Lin, Linan Dong, Fangyi Liu, Ping Liang","doi":"10.4103/jcrt.jcrt_2315_23","DOIUrl":"10.4103/jcrt.jcrt_2315_23","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess the efficacy and safety of the three-dimensional visualization ablation planning system (3DVAPS) in ultrasound-guided percutaneous microwave ablation (US-PMWA) for malignant adrenal tumors (MATs).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on a cohort of 62 unilateral MAT cases from March 2011 to November 2022. There were a total of 62 lesions, with a mean maximum diameter of 5.4 ± 2.7 cm (range, 1.4-15.7 cm). The patients were categorized into the following, based on the pre-operative planning method: 3D planning (n = 32) and 2D planning (n = 30) groups. A comparative analysis was performed on various parameters, including ablation techniques, tumor-related prognosis, and incidence of complications. This analysis encompassed indicators, such as overall survival (OS) rate and local tumor progression (LTP), among others.</p><p><strong>Results: </strong>The median follow-up period was 30 months (range, 3-84 months). Notably, compared with the 2D planning group, the 3D planning group exhibited significant disparities in the number of punctures (P = 0.035) and incidence of complications (P = 0.029) and had no significant difference in the OS ( P > 0.05) but had a significantly lower LTP rate (6.2% vs. 23.3%, P = 0.033). In the 3D planning group, the sub-group with a tumor diameter of < 5 cm exhibited a significantly less number of punctures ( P = 0.039), lower input energy ( P = 0.002), and a shorter ablation time ( P = 0.001), compared with the sub-group with a tumor diameter of ≥ 5 cm, but there was no significant difference in the LTP and OS rates between the two sub-groups ( P > 0.05).</p><p><strong>Conclusions: </strong>The use of 3DVAPS in US-PMWA of MATs was advantageous, especially in lesions with a diameter of ≥ 5 cm. It can help in developing more rational surgical plans, reducing the incidence of complications, and extending the local recurrence-free survival time of patients and can add a certain value for precise treatment and expand the indications for ablation.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"1232-1240"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study. 替赛珠单抗和瑞戈非尼联合治疗晚期肝细胞癌的疗效和安全性分析:一项前瞻性临床研究。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2376_23
Pengfei Sun, Ying Zhang, Shilin Tian, Kai Cui, Jingtao Zhong, Chengsheng Zhang, Dongxu Wang, Bo Zhang, Xuetao Shi, Zhongchao Li
{"title":"Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.","authors":"Pengfei Sun, Ying Zhang, Shilin Tian, Kai Cui, Jingtao Zhong, Chengsheng Zhang, Dongxu Wang, Bo Zhang, Xuetao Shi, Zhongchao Li","doi":"10.4103/jcrt.jcrt_2376_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2376_23","url":null,"abstract":"<p><strong>Backgrounds: </strong>Programmed death receptor 1 (PD-1) monoclonal antibody has been approved for the first and second-line treatments of hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of tislelizumab + regorafenib as a second-line treatment option for advanced HCC.</p><p><strong>Methods: </strong>Treatment-related adverse events (TRAEs) were the primary endpoints in this clinical trial comprising 28 patients with advanced HCC. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).</p><p><strong>Results: </strong>According to the mRECIST 1.1 evaluation criteria, the ORR was 28.6%. Complete and partial response were observed in 3 and 5 patients, respectively; stable disease was observed in 12 patients (DCR, 71.4%). The median PFS was 6.4 months. The incidence of grade 1-2 and 3-4 TRAEs was 57.1% and 39.3%, respectively.</p><p><strong>Conclusion: </strong>This study suggests that tislelizumab + regorafenib can be used as a second-line treatment for advanced HCC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1344-1349"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of robotic-assisted navigation system for CT-guided thoracic and abdominal lesion puncture: A prospective clinical study. 机器人辅助导航系统在 CT 引导下进行胸腔和腹腔病灶穿刺的评估:前瞻性临床研究。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_373_24
Yifan Jing, Jian Zhang, Yong Jin, Xuming Bai
{"title":"Evaluation of robotic-assisted navigation system for CT-guided thoracic and abdominal lesion puncture: A prospective clinical study.","authors":"Yifan Jing, Jian Zhang, Yong Jin, Xuming Bai","doi":"10.4103/jcrt.jcrt_373_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_373_24","url":null,"abstract":"<p><strong>Introduction: </strong>The study aims to compare the accuracy and safety of robotic-assisted navigation puncture to freehand puncture during computed tomography (CT)-guided percutaneous needle insertion in the chest and abdomen.</p><p><strong>Methods: </strong>A total of 60 patients required percutaneous puncture procedures, with 40 involving the chest and 20 involving the abdomen. Eligible patients were randomly assigned to two groups. The test group punctured using a robotic-assisted navigation system, whereas the control group punctured manually. The primary outcome assessment standards are single puncture success rates, with the number of needle modifications and CT scan timings during the procedure serving as supplementary outcome evaluation standards. The Wilcoxon rank sum test is used for the comparison.</p><p><strong>Results: </strong>The puncture procedure's success rates after just one puncture: The test group punctures accurately without adjusting the puncture needle, while the control group uses an average number of 1.73 ± 1.20 pins. The once-puncture success rate of robot navigation puncture is considerably higher than that of bare-handed puncture (P < 0.001). The times of CT scan are necessitated when the puncture is in place: the average times in the test group is 3.03 ± 0.18 times, while the control group is 4.70 ± 1.24 times.</p><p><strong>Conclusion: </strong>In conclusion, the robotic-assisted navigation system improves puncture accuracy while reducing the need for needle corrections during percutaneous puncture procedures. It also shortens CT scans and reduces radiation exposure from X-rays.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1350-1356"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computed tomography-guided radioactive iodine-125 seed implantation for liver malignancies in challenging locations. 计算机断层扫描引导下的放射性碘-125粒子植入术治疗高难度部位的肝脏恶性肿瘤。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2638_22
Lin Li, Shuhui Tian, Xujian Han, Jing Tian, Cunjing Zhang
{"title":"Computed tomography-guided radioactive iodine-125 seed implantation for liver malignancies in challenging locations.","authors":"Lin Li, Shuhui Tian, Xujian Han, Jing Tian, Cunjing Zhang","doi":"10.4103/jcrt.jcrt_2638_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2638_22","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to retrospectively assess the safety and efficacy of radioactive iodine-125 (I-125) seed implantation for liver malignancies in challenging locations.</p><p><strong>Materials and methods: </strong>Between December 2015 and December 2021, 49 patients with 60 liver malignancies in challenging locations who underwent computed tomography (CT)-guided I-125 seed implantation were retrospectively analyzed. The primary endpoints included technical success rate and overall survival (OS), whereas the secondary endpoints included progression-free survival (PFS), disease control rate (DCR), objective response rate (ORR), and liver recurrence. Potential factors associated with liver recurrence were also evaluated.</p><p><strong>Results: </strong>The technical success rate was 100%. The median follow-up duration was 12 months (range, 2-68 months). The mean OS and PFS were 17.58 months (95% CI: 13.64-21.52 months) and 13.14 months (95% CI: 10.36-15.92 months), respectively. The 2-month, 6-month, and 1-year DCR and ORR were 97.96% and 93.88%, 93.75% and 77.08%, and 93.48% and 60.87%, respectively. The 6- and 12-month tumor recurrence rates were 20.41% and 28.26%, respectively. The Kaplan-Meier method was used to estimate the time of liver recurrence, with our results showing that patients with primary intrahepatic cholangiocarcinoma had an increased likelihood of having earlier liver recurrence. No major complications developed during follow-up.</p><p><strong>Conclusion: </strong>CT-guided radioactive I-125 implantation could be a safe and effective alternative with promising survival benefits and high local control rates for liver malignancies in challenging locations.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1165-1172"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report. 胰腺癌永久性碘-125粒子间质近距离治疗指南(2023年版)》:中国专家共识研讨会报告。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2368_23
Bin Liu, Wei Huang, Fujun Zhang, Junjie Wang, Jinhe Guo, Xuequan Huang, Guangyan Lei, Juan Wang, Xin Ye, Ruoyu Wang, Baodong Gai, Xiaokun Hu, Maoquan Li, Chengli Li, Yueyong Xiao, Zhengyu Lin, Lizhi Niu, Guangyu Zhu, Fei Gao, Hongxin Niu, Hongtao Zhang, Qing Wu, Jijin Yang, Hong Zhao, Kaixian Zhang, Zhijin Chen, Tingsong Chen, Haoren Zhang, Zhongmin Wang, Yuliang Li
{"title":"Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report.","authors":"Bin Liu, Wei Huang, Fujun Zhang, Junjie Wang, Jinhe Guo, Xuequan Huang, Guangyan Lei, Juan Wang, Xin Ye, Ruoyu Wang, Baodong Gai, Xiaokun Hu, Maoquan Li, Chengli Li, Yueyong Xiao, Zhengyu Lin, Lizhi Niu, Guangyu Zhu, Fei Gao, Hongxin Niu, Hongtao Zhang, Qing Wu, Jijin Yang, Hong Zhao, Kaixian Zhang, Zhijin Chen, Tingsong Chen, Haoren Zhang, Zhongmin Wang, Yuliang Li","doi":"10.4103/jcrt.jcrt_2368_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2368_23","url":null,"abstract":"<p><strong>Abstract: </strong>The incidence of pancreatic cancer is increasing worldwide. Approximately, 60% of patients with pancreatic cancer have distant metastases at the time of diagnosis, of which only 10% can be removed using standard resection. Further, patients derive limited benefits from chemotherapy or radiotherapy. As such, alternative methods to achieve local control have emerged, including permanent iodine-125 seed interstitial brachytherapy. In 2023, the Chinese College of Interventionalists, affiliated with the Chinese Medical Doctor Association, organized a group of multi-disciplinary experts to compose guidelines for this treatment modality. The aim of this conference was to standardize the procedure for permanent iodine-125 seed interstitial brachytherapy, including indications, contraindications, pre-procedural preparation, procedural operations, complications, efficacy evaluation, and follow-up.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1124-1129"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines for power and time variables for microwave ablation in porcine lung in vitro. 猪肺体外微波消融的功率和时间变量指南。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_817_23
Hongchao Cai, Guanglian Shan, Zhigang Wei, Wenhua Zhao, Guoliang Xue, Chao Zhang, Xin Ye
{"title":"Guidelines for power and time variables for microwave ablation in porcine lung in vitro.","authors":"Hongchao Cai, Guanglian Shan, Zhigang Wei, Wenhua Zhao, Guoliang Xue, Chao Zhang, Xin Ye","doi":"10.4103/jcrt.jcrt_817_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_817_23","url":null,"abstract":"<p><strong>Purpose: </strong>Determination of the appropriate ablative parameters is the key to the success and safety of microwave ablation (MWA) of lung tumors. The purpose of this study was to provide guidelines and recommendations for the optimal time and power for lung tumor MWA.</p><p><strong>Material and methods: </strong>MWA using a 2450-MHz system was evaluated in a porcine lung. The independent variables were power (30, 40, 50, 60, 70, and 80 W) and time (2, 4, 6, 8, 10, and 12 min), and the outcome variable was the volume of ablation. Lung tissues were procured after MWA for measurement and histological evaluation. Analysis of variance was used for statistical analysis, followed by least significant difference (LSD) t-tests where appropriate. A P value of <0.05 was considered statistically significant.</p><p><strong>Results: </strong>The outcome variable (ablative volume) was significantly affected by time, power, and time/power interaction (P < 0.05). When the total output energy was kept constant, the combination of higher power and shorter time obtained a larger ablative volume, especially in the low- and medium-energy groups (P < 0.01).</p><p><strong>Conclusions: </strong>We propose guidelines for ablative volume based on different time and power variables to provide a reference for clinical applications.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 4","pages":"1150-1156"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcutaneous electrical acupoint stimulation for alleviating pain in patients with advanced pancreatic cancer. 经皮穴位电刺激缓解晚期胰腺癌患者的疼痛。
Journal of cancer research and therapeutics Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.4103/jcrt.jcrt_2172_23
Wei Tian, Yun Zhang, Bingjie Yu, Haiyan Jin, Wen Wang, Ting Yuan, Shulin Yu, Haiyan Lu
{"title":"Transcutaneous electrical acupoint stimulation for alleviating pain in patients with advanced pancreatic cancer.","authors":"Wei Tian, Yun Zhang, Bingjie Yu, Haiyan Jin, Wen Wang, Ting Yuan, Shulin Yu, Haiyan Lu","doi":"10.4103/jcrt.jcrt_2172_23","DOIUrl":"10.4103/jcrt.jcrt_2172_23","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related deaths globally, with a five-year survival rate of only 5%.</p><p><strong>Objectives: </strong>Pancreatic ductal adenocarcinoma is often fatal because of the lack of specific early symptoms and effective early screening tools. Therefore, 80%-85% of patients are usually diagnosed in the advanced stages. This study aimed to investigate the analgesic effect of transcutaneous electrical acupoint stimulation in patients with advanced pancreatic cancer.</p><p><strong>Methods: </strong>Eighty patients with advanced pancreatic cancer were recruited from the Integrative Medicine Department of our hospital between June 2017 and October 2018 and randomly divided into the experimental group ( n = 40) and the control group ( n = 40). The experimental group received transcutaneous electrical acupoint stimulation combined with analgesic medication for 3 consecutive days, while the control group received only analgesic medication. The pain scores of the two groups before and after intervention were compared.</p><p><strong>Results: </strong>The mean pain severity score was significantly lower in the experimental group than in the control group on day 1 ( P < 0.001), day 2 ( P < 0.001), day 3 ( P = 0.005), and day 4 ( P = 0.043).</p><p><strong>Conclusion: </strong>Transcutaneous electrical acupoint stimulation therapy effectively alleviates the pain of patients with advanced pancreatic cancer with a high degree of safety and minimal adverse effects, and is worthy of clinical application.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"1334-1337"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141473967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信